Barrington Research Lowers Orthofix Medical (NASDAQ:OFIX) Price Target to $17.00

Orthofix Medical (NASDAQ:OFIX) had its price objective cut by stock analysts at Barrington Research from $18.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Barrington Research’s target price would indicate a potential upside of 30.37% from the company’s current price.

Several other research analysts also recently commented on OFIX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. TD Cowen initiated coverage on Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Orthofix Medical in a research report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Orthofix Medical has an average rating of “Hold” and a consensus target price of $19.80.

Orthofix Medical Stock Up 2.3%

Orthofix Medical stock traded up $0.29 during trading hours on Wednesday, hitting $13.04. The company had a trading volume of 369,811 shares, compared to its average volume of 241,008. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $18.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The firm has a market capitalization of $516.38 million, a P/E ratio of -4.30 and a beta of 0.78. The firm’s fifty day moving average is $14.22 and its 200-day moving average is $14.72.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.44 by ($0.50). The firm had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. Orthofix Medical had a negative net margin of 14.56% and a negative return on equity of 25.59%. On average, research analysts forecast that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Transactions at Orthofix Medical

In related news, CFO Julie Andrews sold 4,873 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $14.38, for a total value of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares of the company’s stock, valued at $834,600.82. The trade was a 7.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 9,797 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $15.21, for a total value of $149,012.37. Following the completion of the transaction, the chief executive officer directly owned 217,237 shares in the company, valued at approximately $3,304,174.77. This represents a 4.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 24,270 shares of company stock valued at $370,958. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CWM LLC grew its holdings in shares of Orthofix Medical by 99.0% in the 3rd quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 955 shares in the last quarter. State of Alaska Department of Revenue bought a new position in Orthofix Medical in the third quarter valued at approximately $30,000. Kestra Advisory Services LLC bought a new position in Orthofix Medical in the fourth quarter valued at approximately $56,000. Mackenzie Financial Corp acquired a new position in shares of Orthofix Medical during the 3rd quarter worth approximately $148,000. Finally, Strs Ohio bought a new stake in shares of Orthofix Medical during the 1st quarter worth approximately $150,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Key Stories Impacting Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Q4 revenue essentially matched analysts’ expectations — reported net sales of roughly $219M vs. consensus near $218.7M — offering some reassurance on demand across the business. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
• Positive Sentiment: Company provided a slide deck, conference call and updated three‑year targets, increasing disclosure and giving investors more detail on the plan to optimize channels and margin recovery. Listen to Conference Call / Slide Deck
• Neutral Sentiment: Management extended the timeline for reaching a 6.5%–7.5% sales CAGR through 2028 as channel optimization efforts mature — signals a clearer plan but delays peak-growth timing. Orthofix extends timeline for 6.5%-7.5% sales CAGR through 2028 as channel optimization matures
• Negative Sentiment: EPS missed materially — Orthofix reported a Q4 EPS result that fell short of consensus (company reported negative/adjusted shortfall vs. analyst estimates), which is weighing on near‑term sentiment. Orthofix (OFIX) Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: FY‑2026 revenue guidance of $850M–$860M comes in slightly below street consensus (~$861.4M), leaving limited near‑term upside to estimates and contributing to cautious analyst outlooks. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
• Negative Sentiment: Company is excluding results from its discontinued M6™ product lines in pro‑forma measures — a short‑term headwind to reported results and margins, though management frames this as part of a longer‑term optimization. Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.